Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03792256 · ClinicalTrials.gov registry record · Phase 1
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
A Phase 1 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03792256 is a Phase 1 study that has completed, run by Children's Oncology Group. The registered enrollment target is 12 participants.
The verdict
NCT03792256, a Phase 1 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
AINV18P1 is a Phase 1 study where palbociclib will be administrated in combination with a standard re-induction platform in pediatric relapsed Acute Lymphoblastic Leukemia (ALL) and lymphoblastic lymphoma (LL). LL patients are included because the patient population is rare and these patients are most commonly treated with ALL regimens. The proposed palbociclib starting dose for this study will be 50 mg/m\^2/day for 21 days.
Interventions
- DRUG Doxorubicin
- DRUG Palbociclib
- DRUG Cytarabine
- DRUG Methotrexate
- DRUG Hydrocortisone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-04-11 |
| Est. Completion | 2023-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03792256
The ClinicalTrials.gov registry entry for NCT03792256 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT03792256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03792256 about?
NCT03792256 is a clinical study titled "Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)". AINV18P1 is a Phase 1 study where palbociclib will be administrated in combination with a standard re-induction platform in pediatric relapsed Acute Lymphoblastic Leukemia (ALL) and lymphoblastic lymphoma (LL). LL patients are included because the patient population is rare and these patients are mo...
What is the current status of trial NCT03792256?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-04-11. Estimated completion is 2023-09-30.
What interventions are being tested in trial NCT03792256?
The interventions under investigation include: Doxorubicin (DRUG), Palbociclib (DRUG), Cytarabine (DRUG), Methotrexate (DRUG), Hydrocortisone (DRUG).
Who is sponsoring clinical trial NCT03792256?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.